Formed in 2012, DeuteRx is a virtual biopharmaceutical company focused on improving racemic drugs for patients. Our team has pioneered the use of Deuterium-Enabled Chiral Switching (DECS) to isolate a single stereoisomer from a mixture of interconverting stereoisomers. This revolutionary strategy stabilizes the preferred stereoisomer in existing drugs sold as racemic mixtures to reduce deleterious side-effects and improve efficacy. We have applied DECS to a wide range of clinical therapies, including the deuterium-stabilized R-stereoisomer of pioglitazone for nonalcoholic steatohepatitis (NASH) (PXL065, acquired by Poxel in 2018) and the deuterium-stabilized S-stereoisomer of lenalidomide (DRX-053, acquired by Celgene in 2012).
Location: United States, Massachusetts, Andover
Member count: 1-10
Total raised: $2.8M
Founded date: 2012
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 30.09.2015 | Seed | $2.8M | - | finsmes.co... |
Mentions in press and media 1
| Date | Title | Description | Category | Author | Source |
| 30.09.2015 | DeuteRx Ra... | DeuteRx LLC, a Boston, MA-base... | USA | - | finsmes.co... |